Amrubicin
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.[2]
Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3] [4]
It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]
References
References
- ↑ Ueoka H, Ohnoshi T, Kimura I (November 1992). “[New anthracycline analogues in the treatment of lung cancer]”. Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.
- ↑ Sumitomo Pharmaceuticals Co., Ltd. (2003). “CALSED for Injection (English)” (PDF). Retrieved 2008-08-17.
- ↑ Celgene Corporation (2008). “Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer”. Retrieved 2009-07-10.
- ↑ Medical News Today (2007). “Pharmion’s Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer”. Retrieved 2009-07-10.
- ↑ Ohmori H, Tsushima T, Kobashi K (April 1996). “[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]”. Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.
- ↑ Tsushima K, Sakata Y, Munakata A; et al. (June 1991). “[A phase II study of SM-5887 for advanced gastric cancer]”. Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH